SLDB Solid Biosciences Inc
Price (delayed)
$5.25
Market cap
$406.84M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.06
Enterprise value
$350.78M
Solid Biosciences is a life sciences company focused on advancing transformative treatments to improve the lives of patients living with Duchenne. Disease-focused and founded by a family directly impacted by
Highlights
The EPS rose by 37% year-on-year
The debt fell by 8% YoY and by 2.2% QoQ
The equity has declined by 18% since the previous quarter but it is up by 9% year-on-year
SLDB's quick ratio is down by 42% year-on-year and by 34% since the previous quarter
The net income fell by 30% YoY and by 22% QoQ
Key stats
What are the main financial stats of SLDB
Market
Valuations
Earnings
Shares outstanding
77.49M
Market cap
$406.84M
Enterprise value
$350.78M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.53
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$129.73M
Net income
-$124.7M
EBIT
-$124.36M
EBITDA
-$119.51M
Free cash flow
-$100.66M
Per share
Balance sheet
Liquidity
EPS
-$3.06
EPS diluted
-$3.06
Free cash flow per share
-$2.47
Book value per share
$3.44
Revenue per share
$0
TBVPS
$4.62
Total assets
$188.66M
Total liabilities
$51.42M
Debt
$24.18M
Equity
$137.25M
Working capital
$127.05M
Debt to equity
0.18
Current ratio
5.2
Quick ratio
4.92
Net debt/EBITDA
0.47
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-56.7%
Return on equity
-70.4%
Return on invested capital
-92.4%
Return on capital employed
-78.5%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
SLDB stock price
How has the Solid Biosciences stock price performed over time
Intraday
-8.38%
1 week
-4.55%
1 month
33.25%
1 year
-57.07%
YTD
31.25%
QTD
31.25%
Financial performance
How have Solid Biosciences's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$129.73M
Net income
-$124.7M
Gross margin
N/A
Net margin
N/A
The net income fell by 30% YoY and by 22% QoQ
The operating income has declined by 24% year-on-year and by 16% since the previous quarter
Growth
What is Solid Biosciences's growth rate over time
Valuation
What is Solid Biosciences stock price valuation
P/E
N/A
P/B
1.53
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS rose by 37% year-on-year
The equity has declined by 18% since the previous quarter but it is up by 9% year-on-year
The price to book (P/B) is 11% more than the 5-year quarterly average of 1.5 and 4.4% more than the last 4 quarters average of 1.6
Efficiency
How efficient is Solid Biosciences business performance
The ROIC is down by 22% QoQ and by 7% YoY
Solid Biosciences's return on equity has decreased by 20% QoQ and by 13% YoY
The return on assets has declined by 19% since the previous quarter and by 16% year-on-year
Dividends
What is SLDB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for SLDB.
Financial health
How did Solid Biosciences financials performed over time
SLDB's quick ratio is down by 42% year-on-year and by 34% since the previous quarter
Solid Biosciences's current ratio has decreased by 42% YoY and by 34% QoQ
The debt is 82% lower than the equity
The debt to equity has grown by 20% from the previous quarter but it has contracted by 14% YoY
The equity has declined by 18% since the previous quarter but it is up by 9% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.